Research, development, production and distribution of nutritional health supplements,
dermocosmetics, dietary foods for special medical purposes and medical devices
<a href="/events">We will be present </a>
<a href="/about-us/quality">Certified quality</a>

Amnol is committed to maintaining the quality of its products and manufacturing processes, ISO 9001 and ISO 22716 (GMP for cosmetic products) certifications, and by the compliance with the FDA code CFR 21 (GMP for food supplements). The company guarantees excellence in its nutritional health supplements, dermocosmetics and medical devices by means of scrupulous methods of control and state of the art instruments, thus safeguarding the well-being of end users.

<a href="/expert">Ask the expert</a>

Our experts are at your disposal for any enquiries you may have regarding Amnol's products and will respond to your requests for any further information or informative literature. Please contact them by email or call on our toll free number.

News from the world

News from the world

  • Response to the letter to the editor: "New data fo...
    Response to the letter to the editor: "New data for venous thromboembolism in patients with small cell lung cancer: A review". ...
  • Comparison of cyanoacrylate closure and radiofrequ...
    CONCLUSIONS: This trial continues to demonstrate the safety and efficacy of cyanoacrylate closure for the treatment of great saphe...
  • Response to "Commentary on pelvic venous reflux in...
    Response to "Commentary on pelvic venous reflux in males with varicose veins and recurrent varicose veins". Phlebology. 2...
  • Neck vein obstruction: Diagnosis and the role of c...
    CONCLUSION: Further research to validate this diagnostic protocol is required. PMID: 30360684 [PubMed - as supplied by publish]...
  • Venous thromboembolism prevention in lower limb tr...
    Authors: Langridge BJ, Goodall RJ, Onida S, Shalhoub J, Davies AH PMID: 30354874 [PubMed - as supplied by publisher] (Source: ...
  • Publication of UK NICE Clinical Guidelines 168 has...
    Conclusions Disappointingly, we have been unable to demonstrate that publication of NICE CG168 has been associated with a meaningf...
  • A history of injection treatments - II sclerothera...
    Conclusion Sclerotherapy principles were established long ago, although current modifications have been made possible by the intro...
  • Performance changes of venous valves following tis...
    Conclusions The developed in vitro model was shown to be an effective method for measuring the performance of venous valves. The o...
  • Percutaneous sclerotherapy of para-orbital and orb...
    Conclusions Percutaneous sclerotherapy of orbital Venous Malformations with bleomycin is a safe and well-controlled procedure done...
  • Retrospective cohort study for evaluating the INR ...
    Conclusion Our study revealed only one-third of the follow-up time to be spent within therapeutic INR, association of INR therapeu...
Newsletter

Newsletter

Sign up to our newsletter to keep up-to-date about what's new at AMNOL.








AMNOL Chimica Biologica S.r.l.
Registered office, Administrative and Sales Offices: Corso della Vittoria 14, 28100 Novara
Tel: +39 0321 499199 - Email: info@amnol.net
Share Capital € 250,000 issued capital R.E.A. Novara 10937 VAT code 01228730030 Tax Code 04170400156



AMNOL Chimica Biologica and Euronational are companies of the WTB group (company subject to management and co-ordination activity pursuant to Art.2497 CC by WTB Holding S.p.A. - Milan)


Quality Management System ISO 9001, GMP COSMETICS ISO 22716 and compliance with GMP FOOD SUPPLEMENTS (FDA CFR 21-part 111) issued by Bureau Veritas Italia SpA

Copyright 2018 by Amnol Chimica Biologica